Clinical management of metastatic colorectal cancer in the era of precision medicine
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
AKT/PKB signaling: navigating the network
The Ser and Thr kinase AKT, also known as protein kinase B (PKB), was discovered 25
years ago and has been the focus of tens of thousands of studies in diverse fields of biology …
years ago and has been the focus of tens of thousands of studies in diverse fields of biology …
The PI3K pathway in human disease
Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth
factor receptors, and elevated PI3K signaling is considered a hallmark of cancer. Many PI3K …
factor receptors, and elevated PI3K signaling is considered a hallmark of cancer. Many PI3K …
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Abstract Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
signaling is one of the most important intracellular pathways, which can be considered as a …
signaling is one of the most important intracellular pathways, which can be considered as a …
PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects
Breast cancer is a serious health problem worldwide, representing the second cause of
death through malignancies among women in developed countries. Population …
death through malignancies among women in developed countries. Population …
RAS-targeted therapies: is the undruggable drugged?
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
[HTML][HTML] Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Y Feng, M Spezia, S Huang, C Yuan, Z Zeng, L Zhang… - Genes & diseases, 2018 - Elsevier
As the most commonly occurring cancer in women worldwide, breast cancer poses a
formidable public health challenge on a global scale. Breast cancer consists of a group of …
formidable public health challenge on a global scale. Breast cancer consists of a group of …
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde… - Science translational …, 2014 - science.org
The development of noninvasive methods to detect and monitor tumors continues to be a
major challenge in oncology. We used digital polymerase chain reaction–based …
major challenge in oncology. We used digital polymerase chain reaction–based …
[HTML][HTML] Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …
variable sensitivity to therapeutics and may play different roles in progression. We previously …